Elevated Levels of Endoglin, Endostatin, FGF-α, HGF, and Thrombospondin-2 in Aqueous Humor of nAMD Patients

Ocul Immunol Inflamm. 2022 Jul;30(5):1092-1098. doi: 10.1080/09273948.2020.1869785. Epub 2021 Apr 1.

Abstract

Purpose: to explore the aqueous cytokine profiles in nAMD patients before and after conbercept therapy.

Methods: aqueous levels of 17 cytokines were detected in 20 treatment-naïve nAMD eyes and 20 age- and sex-matched age-related cataract (ARC) eyes. All of the nAMD patients received three intravitreal injections of conbercept. The central macular thickness (CMT) and maximum retinal thickness-3 mm (MRT-3 mm) were measured by SD-OCT. Fundus fluorescein angiography (FA) was used to measure the greatest linear diameter (GLD).

Results: Aqueous endoglin, endostatin, FGF-α, HGF, and thrombospondin-2 levels were significantly higher in the nAMD group than those in the ARC group, whether before or after two conbercept injections. In the nAMD group, baseline thrombospondin-2 was positively correlated with GLD. Baseline FGF-α, thrombospondin-2, and VEGF-A were positively correlated with MRT-3 mm. After two conbercept injections, endostatin levels were positively correlated with VEGF-A.

Conclusions: Endoglin, endostatin, FGF-α, HGF, and thrombospondin-2 may participate in the pathogenesis of nAMD.

Keywords: Neovascular age-related macular degeneration; anti-VEGF; aqueous humor; conbercept; cytokines; inflammation.

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use
  • Aqueous Humor*
  • Cytokines
  • Endoglin
  • Endostatins
  • Hepatocyte Growth Factor
  • Humans
  • Intravitreal Injections
  • Ranibizumab
  • Thrombospondins
  • Vascular Endothelial Growth Factor A
  • Wet Macular Degeneration* / drug therapy

Substances

  • Angiogenesis Inhibitors
  • Cytokines
  • Endoglin
  • Endostatins
  • HGF protein, human
  • Thrombospondins
  • Vascular Endothelial Growth Factor A
  • Hepatocyte Growth Factor
  • Ranibizumab